Printer Friendly

SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION COMPLETE MERGER TO FORM SCIOS NOVA INC.

 SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION
 COMPLETE MERGER TO FORM SCIOS NOVA INC.
 MOUNTAIN VIEW, Calif., Sept. 4 /PRNewswire/ -- Scios Inc. (NASDAQ: SCIO) and Nova Pharmaceutical Corporation (NASDAQ: NOVX), Baltimore, Md., announced today that they have completed the merger of the two companies. Effective immediately, the combined company is Scios Nova Inc. At separate meetings held Sept. 3, stockholders of both companies approved the merger.
 Effective at the opening of trading today, the common stock of Scios Nova Inc. will trade under the symbol "SCIO" and Scios Nova Inc. Class C and Class D warrants will trade under symbols SCIOW and SCIOZ, respectively.
 The common stock and warrants of Nova ceased trading on the NASDAQ National Market System at the close of trading Thursday, Sept. 3. Nova stock holders and warrant holders will soon receive in the mail a packet of materials explaining the procedure for exchanging their securities from the First National Bank of Boston.
 Scios Nova Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel human therapeutics. Scios Nova focuses its efforts in four areas: cardiovascular disease, inflammation, metabolic disorders and tissue repair. The company's drug discovery technology encompasses both biotechnology techniques and small molecule design to develop new biopharmaceutical products. Scios Nova develops and commercializes products on a proprietary basis and in collaboration with established companies.
 -0- 9/4/92
 /CONTACT: Virginia Walker, 415-940-6634 or -6631, or Kira Bacon, 410-558-9465, of Scios Nova Inc.; or Lynne Brum of Feinstein Partners, 617-577-8110, for Scios Nova Inc./
 (SCIO NOVX) CO: Scios Nova Inc. ST: California, Maryland IN: MTC SU: TNM


CN -- NE002 -- 6796 09/04/92 08:28 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 4, 1992
Words:275
Previous Article:CARL KARCHER ENTERPRISES REPORTS EARNINGS
Next Article:CIRCUIT CITY STORES, INC. REPORTS AUGUST SALES
Topics:


Related Articles
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION AGREE TO MERGE
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION MERGER CLEARS FTC REVIEW
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION BEGIN DISTRIBUTION OF PROXY STATEMENT TO STOCKHOLDERS
SCIOS NOVA INC. RAISES $7.95 MILLION THROUGH EXERCISE OF WARRANTS
SCIOS INC. AND NOVA PHARMACEUTICAL CORPORATION RECEIVE STOCKHOLDER APPROVALS TO MERGE THE TWO COMPANIES
SCIOS NOVA REPORTS THIRD QUARTER AND NINE-MONTH 1992 FINANCIAL RESULTS
SCIOS NOVA EXERCISES OPTION TO PURCHASE INTERESTS IN NOVA TECHNOLOGY LIMITED PARTNERSHIP
Scios Board to Oppose Proxy Contest by Randal J. Kirk.
Scios Board Mails Letter and Proxy Statement to Stockholders For February 28, 2000 Annual Meeting.
Scios and R. J. Kirk Agree to End Proxy Contest.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters